Skip to main content
. 2006 Aug 29;95(6):677–682. doi: 10.1038/sj.bjc.6603321

Table 5. Antitumour activity by dose (RECIST).

    Evaluable (n=23)
Dose (mg m−2) Number of patients CR PRa s.d. PD NE
300 3 0 0 2 0 1
500 3 0 2 0 0 0
600 3 0 0 1 0 0
700 6 0 1 3 1 0
800 3 0 1 0 1 1
900 4 0 0 2 0 1
1000 3 0 0 1 1 0
1200 6 0 1 2 1 0
Total 31 0 5 11 4 3

NSCLC=non-small cell lung cancer; CR=complete response; NE=not evaluated; PD=progressive disease; PR=partial response; s.d.=stable disease.

a

In addition, one NSCLC patient at 500 mg m−2 had PR via WHO criteria.